Chemotherapy Drug Linked to Stem Cell Damage
Researchers found that doxorubicin exposure alters human stem cells, impacting the function of heart cells they later produce.
Updated on Oct. 10, 2026 in Heart Disease
Live Poll
Does understanding cellular side effects of chemotherapy increase your concern about long-term cardiac health?
A new study reveals that exposing human induced pluripotent stem cells (iPSCs) to the chemotherapy drug doxorubicin induces transcriptional reprogramming. This process causes lasting functional impairments in the resulting cardiomyocytes, including reduced contractility.
Why it matters
The findings suggest that doxorubicin-induced mitochondrial dysfunction during early stem cell stages creates durable changes in the energy metabolism of heart cells. This may explain why young patients treated with the drug could face long-term cardiac issues.
Researchers observed that doxorubicin treatment causes increased mitochondrial fragmentation and reduced ATP levels in stem cells without triggering apoptosis. The study identified transcriptional reprogramming in energy metabolism pathways during the differentiation process.
The players
Human induced pluripotent stem cells (iPSCs)
These are specialized cells reprogrammed from adult cells that have the ability to differentiate into any cell type, including heart muscle.
Doxorubicin
This is a potent chemotherapy medication commonly used to treat various types of cancer by interfering with cancer cell growth.
The details
Using a human iPSC-based model, investigators performed whole genome transcriptome profiling to track cellular responses after short-pulse exposures to the drug. The resulting cardiomyocytes displayed impaired calcium handling and a diminished capacity for cardiac muscle regeneration.
Timeline
The research findings were published on October 10, 2026.
The Big Picture
This study advances the ongoing study of anthracycline-induced cardiotoxicity by identifying a potential mechanism rooted in stem cell biology. It provides new insights into how chemotherapy drugs can cause long-term physiological damage beyond their immediate cytotoxic effects.
These findings help scientists better understand the long-term cardiac side effects that may affect children and teenagers who undergo chemotherapy. This information could eventually lead to improved screening protocols or protective strategies for young patients receiving doxorubicin treatments.
The takeaway
The study highlights that chemotherapy drugs can impact the development of future cells even after treatment concludes. Patients and families should consult with their oncologists to understand potential long-term health monitoring for those treated with chemotherapy at a young age.
Further reading
For additional context on how conditions affect cardiac muscle, visit the Heart Disease section.
More information
Review the full findings in the peer-reviewed research article.
Source note: This article includes information reported by Nature.
Live Poll
Does understanding cellular side effects of chemotherapy increase your concern about long-term cardiac health?
